INTS (Intensity Therapeutics) Insider Ownership: 4.73 % (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INTS Intensity Therapeutics Inc INTS
32 GF Score
Price $4.87
! 1 Warning Sign
View Full Analysis

What is Intensity Therapeutics Insider Ownership?

Intensity Therapeutics INTS -0.78% 32 Insider Ownership is 4.73 % as of Aug. 21, 2026. GuruFocus rates INTS with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Intensity Therapeutics's insider ownership is 4.73%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Intensity Therapeutics's Institutional Ownership is 6.08%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Intensity Therapeutics's Float Percentage Of Total Shares Outstanding is 96.37%.

Intensity Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Intensity Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intensity Therapeutics Insider Ownership Chart

Intensity Therapeutics Historical Data

The historical data trend for Intensity Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 8.02 4.44 4.26 4.26 3.48 3.52 83.43 9.15 4.73 4.73
INTS
32GF Score
Intensity Therapeutics Inc INTS
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intensity Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 4.73 % mean?
Intensity Therapeutics (INTS) has a Insider Ownership of 4.73 % as of Aug. 21, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Intensity Therapeutics and its competitors.
Is Intensity Therapeutics' Insider Ownership too high?
Intensity Therapeutics' current Insider Ownership is 4.73 %. Overall, Intensity Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Intensity Therapeutics' Insider Ownership compare to CALC and INAB?
Intensity Therapeutics' Insider Ownership of 4.73 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Intensity Therapeutics and its competitors. Intensity Therapeutics's current Insider Ownership is 4.73 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intensity Therapeutics stock overvalued right now?
Intensity Therapeutics (INTS) has a current Insider Ownership of 4.73 %. The current Insider Ownership is 4.73 %. Intensity Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Intensity Therapeutics (INTS), the current Insider Ownership is 4.73 % as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intensity Therapeutics Business Description

Address 1 Enterprise Drive, Suite 430, Shelton, CT, USA, 06484-4779
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
32GF Score

Get the complete analysis for INTS

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.87
Price